Crowdfunding: Healthcare Industry

0 days left
Pledged
€103620
Goal
€100000
Backers
267
Funded
Ziya Gaziyev
Ziya Gaziyev
CEO
Corrado Corneo
Corrado Corneo
Financial Director
Schaeffer nutraceuticals 1 Schaeffer nutraceuticals 2 Schaeffer nutraceuticals 3 Schaeffer nutraceuticals 4 Schaeffer nutraceuticals 5 Schaeffer nutraceuticals 6 Schaeffer nutraceuticals 7 Schaeffer nutraceuticals 8 Schaeffer nutraceuticals 9
Schaeffer nutraceuticals 1 Schaeffer nutraceuticals 2 Schaeffer nutraceuticals 3 Schaeffer nutraceuticals 4 Schaeffer nutraceuticals 5 Schaeffer nutraceuticals 6 Schaeffer nutraceuticals 7 Schaeffer nutraceuticals 8 Schaeffer nutraceuticals 9

Invest in VITAPROTEIN

VITAPROTEIN is based on the result of many years of research on signal theory conducted by world-class Professor Dr Günter Blobel who discovered that newly formed protein molecules are equipped with internal signals that allows them to find their way to the membrane of the endoplasmic reticulum, one of the cell’s organelles, and get through this membrane. As early as of the early seventies of the twentieth century, and for over the next 20 years, Professor Blobel described in detail the molecular mechanisms underlying these processes, also showing that this “address label”, or “postcode”, mechanism allows the proteins to travel to other organelles.

As it turned out, the phenomenon discovered and described by Professor Blobel is of a universal character: proteins in yeast, plants and animals behave the same way. The discovery made by Professor Blobel had a major impact on the current research in the field of cell biology. Proteins are continuously being transported through membranes or walls that both separate the cell from its surroundings and separate the inner parts of the cell, the organelles. In 1975 Günter Blobel showed that in certain cases amino acids in a protein serve as an address label that determines where a protein is to be delivered. Amino acid sequences determine whether a protein is to be passed through the membrane out of the cell or into an organelle or is to be built in the membrane.
For his discovery that proteins have intrinsic signals that govern their transport and localization in the cell, Professor Blobel received a Nobel Prize for Medicine or Physiology in 1999.

The Patented Manufacturing Process

The research development of the so-called ‘postcode’ phenomenon embraced by scientific researchers fascinated by the achievement of Prof. Blobel, transformed these theoretical considerations and concepts into a specific technology, supported by clinical and laboratory tests conducted by Dr. med. H. Guse, to prove the high assimilation efficiency in the human body cells of encoded amino acids for preventive care.
The manufacturing process to produce the biologically modified active carrier protein with encoded amino acids of natural origin was patented in 2008 and further modified in 2017.

Proto Global GmbH - Schaeffer Nutraceuticals

Proto Global GmbH has acquired the patent and applied in practice the unique the production technology of the biologically modified active protein carrier with encoded amino acids of natural origin under the registered commercial brand VITAPROTEIN® within the portfolio of SCHAEFFER NUTRACEUTICALS® products.

VITAPROTEIN® is the main ingredient of VIPROACTIVE® dietary supplements. The manufacturing technology is patented in Germany and is pending for patenting in other countries.

QUALITY

Schaeffer Nutraceuticals do not accept compromises on quality. Our work is founded on honesty, integrity and responsibility.
Our mission has always been to take care of people through specific product lines with innovative and proven effectiveness utilizing minimally processed selected ingredients available
in nature while respecting the planet.
In pursuing our business objectives, we have drawn inspiration from certain core values that we apply every day in our work, as well as in relations with employees and with our partners. We owe our success to the aptitude and individual contributions to evolution of a cohesive and integrated team.
Our company promotes and implements transparent conducts consistent with the standards, the rules and principles of social responsibility, an effective contribution to the growing global movement to “reclaim our health”
All ingredients contained in our formulations are from selected and certified suppliers.
Many ingredients are organic and guaranteed by certifications at origin.

SECURITY

  • pledge on existing company's actives
  • pledge on new actives using funds raised via TFGCROWD
  • guarantee of the Borrower

MARKET

Germany – Europe’s Most Important Destination for Pharmaceuticals

Germany has several advantages for pharmaceutical companies, such as its market size, reliable legal framework for approval and reimbursement,  as well as the quality and cost-effectiveness of its clinical research. In 2015, the global pharmaceutical market was 1.07 trillion USD. The US has the  largest market with 433 billion USD, second is China with 115 billion USD, third is Japan with 81 billion USD, and Germany has the world’s fourth largest market with 43 billion USD. The German market is Europe’s largest market. Germany ranks fourth in the world as a location for conducting clinical trials. It has a global market share of 6.7% for all clinical studies, following the US (44%), China (9.8%) and Canada (7.2%).

The European Regulatory System for Pharmaceuticals

The European system provides different routes for authorizing medicines.

Decentralized Procedure

The majority of medicines are authorized by national competent authorities (NCAs) in the member states. There are two NCAs for human drugs in Germany: The Bundesinstitut für Arzneimittel und Medizinprodukte - BfArM (Federal nstitute for Drugs and Medical Devices) and the Paul-Ehrlich-Institut. BfArM is esponsible for licensing all human medicinal products, except sera, vaccines, allergens and blood products which are licensed by the Paul-Ehrlich-Institut. Companies can use one of the following procedures to authorize a drug in several member states:

Decentralized procedure

Companies can apply for simultaneous authorization of a medicine in more than one EU member state provided the drug has not yet been authorized in an EU country and does not fall into the mandatory scope of the centralized procedure.

Mutual-recognition procedure

Companies that have a medicine authorized in one EU member state can apply for recognition of this authorization in other EU countries. This process allows member states to rely on each other’s scientific assessments. Regulations and requirements for pharmaceuticals are identical throughout the EU, irrespective of the authorization route.

Centralized Procedure

Under the centralized procedure, pharma-ceutical companies submit a single marketing authorization application to the European Medicines Agency (EMA).

The centralized procedure is compulsory for certain medicines and is used for most innovative medicines. The EMA’s Committee for Medicinal Products for Human Use (CHMP) conducts a scientific assessment of the application and makes a recommendation on whether or not a marketing authorization should be granted. Once granted by the European Commission, the centralized marketing authorization is valid in the European Economic Area (all 28 EU member states plus Liechtenstein, Iceland and Norway). This single marketing authorization permits the marketing-authorization holder to market the medicinal product and make it available throughout the EU.

Understanding the German Health Care System

Germany has approximately 80.2 million inhabitants. 71.4 million citizens are covered by the GKV (Gesetzliche Krankenversicherung = statutory health insurance), around 8.8 million are covered by the PKV (Private Krankenversicherung = private health insurance) including citizens are insured via state aid. GKV is provided by around 100 statutory health insurance funds. These GKV funds provide comprehensive health care. The GKV is a compulsory insurance system which may only be left in favor of the PKV if certain requirements (annual income, liberal profession, etc.) are met. Health insurance is mandatory for German citizens.

The European Regulatory System for Pharmaceuticals

The European system provides different routes for authorizing medicines.

Decentralized Procedure

The majority of medicines are authorized by national competent authorities (NCAs) in the member states. There are two NCAs for human drugs in Germany: The Bundesinstitut für Arzneimittel und Medizinprodukte - BfArM (Federal nstitute for Drugs and Medical Devices) and the Paul-Ehrlich-Institut. BfArM is esponsible for licensing all human medicinal products, except sera, vaccines, allergens and blood products which are licensed by the Paul-Ehrlich-Institut. Companies can use one of the following procedures to authorize a drug in several member states

Decentralized Procedure

Companies can apply for simultaneous authorization of a medicine in more than one EU member state provided the drug has not yet been authorized in an EU country and does not fall into the mandatory scope of the centralized procedure

Mutual-recognition procedure

Companies that have a medicine authorized in one EU member state can apply for recognition of this authorization in other EU countries. This process allows member states to rely on each other’s scientific assessments. Regulations and requirements for pharmaceuticals are identical throughout the EU, irrespective of the authorization route.

Centralized Procedure

Under the centralized procedure, pharma-ceutical companies submit a single marketing authorization application to the European Medicines Agency (EMA). The centralized procedure is compulsory for certain medicines and is used for most innovative medicines. The EMA’s Committee for Medicinal Products for Human Use (CHMP) conducts a scientific assessment of the application and makes a recommendation on whether or not a marketing authorization should be granted. Once granted by the European Commission, the centralized marketing authorization is valid in the European Economic Area (all 28 EU member states plus Liechtenstein, Iceland and Norway). This single marketing authorization permits the marketing-authorization holder to market the medicinal product and make it available throughout the EU.

Understanding the German

Health Care System

Germany has approximately 80.2 million inhabitants. 71.4 million citizens are covered by the GKV (Gesetzliche Krankenversicherung = statutory health insurance), around 8.8 million are covered by the PKV (Private Krankenversicherung = private health insurance) including citizens are insured via state aid. GKV is provided by around 100 statutory health insurance funds. These GKV funds provide comprehensive health care. The GKV is a compulsory insurance system which may only be left in favor of the PKV if certain requirements (annual income, liberal profession, etc.) are met. Health insurance is mandatory for German citizens.

Loan term
6 months
Interest rate
5% per year
Earnings
0

Other Projects